

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
Jylamvo	EMEA/H/C/3756	L01BA01	metotrexato	Therakind Ltd	26-gen-17	29-mar-17	28-apr-17	10-mag-17	045319011	1
Xeljanz	EMEA/H/C/004214/0000	L04AA29	Tofacitinib	Pfizer Limited	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045320013	1
Xeljanz	EMEA/H/C/004214/0000	L04AA29	Tofacitinib	Pfizer Limited	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045320025	2
Xeljanz	EMEA/H/C/004214/0000	L04AA29	Tofacitinib	Pfizer Limited	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045320037	3
Yargesa	EMEA/H/C/4016/00	A16AX06	miglustat	JensonR+ Limited	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045318019	1
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322017	1
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322029	2
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322031	3
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322043	4
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322056	5
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322068	6
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322070	7
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322082	8
Tadalafil Lilly	EMEA/H/C/004666/0000	G04BE08	tadalafil	Eli Lilly Nederland B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045322094	9
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317017	1
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317029	2
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317031	3
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317043	4
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317056	5
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317068	6
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317070	7
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317082	8
AMGEVITA	EMEA/H/C/004212/0000	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045317094	9
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316015	1
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316027	2
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316039	3
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316041	4
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316054	5
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316066	6
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316078	7
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316080	8
SOLYMBIC	EMEA/H/C/4373	L04AB04	adalimumab	Amgen Europe B.V.	26-gen-17	22-mar-17	28-apr-17	10-mag-17	045316092	9
Rolufta	EMEA/H/C/4654	R03BB07	Umeclidinio	GlaxoSmithKline Trading Services Limited	26-gen-17	20-mar-17	28-apr-17	10-mag-17	045321015	1
Rolufta	EMEA/H/C/4654	R03BB07	Umeclidinio	GlaxoSmithKline Trading Services Limited	26-gen-17	20-mar-17	28-apr-17	10-mag-17	045321027	2
Rolufta	EMEA/H/C/4654	R03BB07	Umeclidinio	GlaxoSmithKline Trading Services Limited	26-gen-17	20-mar-17	28-apr-17	10-mag-17	045321039	3
Ledaga	EMEA/H/C/002826/0000	L01AA05	Clometina	Actelion Registration Ltd	15-dic-16	03-mar-17	28-apr-17	10-mag-17	045315013	1
Humira	EMEA/H/C/481/X/157	L04AB04	Adalimumab	AbbVie Ltd	26-gen-17	24-mar-17	28-apr-17	10-mag-17	035946197	20
BeneFIX	EMEA/H/C/000139/X/0139	B02BD09	Nonacog alfa	Pfizer Limited	26-gen-17	22-mar-17	28-apr-17	10-mag-17	035353093	9
Briviact	EMEA/H/C/3898/IAin/1 EMEA/H/C/3898/IA/2/G	N03AX23	brivaracetam	UCB Pharma S.A.	07-apr-16	22-mar-17	28-apr-17	10-mag-17	044698239	23
Briviact	EMEA/H/C/3898/IAin/1 EMEA/H/C/3898/IA/2/G	N03AX23	brivaracetam	UCB Pharma S.A.	07-apr-16	22-mar-17	28-apr-17	10-mag-17	044698241	24
Briviact	EMEA/H/C/3898/IAin/1 EMEA/H/C/3898/IA/2/G	N03AX23	brivaracetam	UCB Pharma S.A.	07-apr-16	22-mar-17	28-apr-17	10-mag-17	044698254	25
Briviact	EMEA/H/C/3898/IAin/1 EMEA/H/C/3898/IA/2/G	N03AX23	brivaracetam	UCB Pharma S.A.	07-apr-16	22-mar-17	28-apr-17	10-mag-17	044698266	26
Briviact	EMEA/H/C/3898/IAin/1 EMEA/H/C/3898/IA/2/G	N03AX23	brivaracetam	UCB Pharma S.A.	07-apr-16	22-mar-17	28-apr-17	10-mag-17	044698278	27

La responsabilità di qualsiasi onere e/o attività che l' Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all' immissione in commercio del medicinale, è totalmente a carico dell' Azienda stessa. L' ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.